Supporting people in hospitals across South Australia through vital health and medical research and improved patient care.
Meet our passionate and dedicated team.
Meet our Board and Governance team.
THRF adopts extremely high transparency standards when reporting our financials.
Supports research into the detection, management & treatment of breast cancer.
Funding research into prostate cancer prevention, detection & treatment.
Improving heart health through advances in knowledge & research to beat heart disease.
Our aim is to reduce & eliminate the high incidence of chronic kidney disease and diabetes.
Supports health and wellbeing research & programs for veterans, emergency service personnel and their families.
Driving collaboration, innovation & research to develop best-practice arts, design & health programs.
Supporting world-class stroke research to improve prevention, diagnosis & acute treatment to cure stroke.
Providing donor stool to treat patients with bowel conditions and foster research into faecal transplant as a treatment.
Do you want to join our team? Check out current career opportunities here.
View some of the commonly asked questions about our organisation.
We are so grateful to those who donate their time and skills to support life-changing medical research. Find out more…
Get in touch with us here.
An exciting project set to explore a newly discovered pathway that could lead to new treatments for metastatic prostate cancer is now underway at the Centre for Cancer Biology (CCB).
Supported by The Hospital Research Foundation, with partner Australian Prostate Cancer, this incredible, innovative research is set to save lives.
While advanced research has ensured that organ-confided prostate cancer is cured in about 70 per cent of cases, metastatic prostate cancer (where the cancer will or has spread around the body) is incurable.
These patients are treated with androgen deprivation therapy which is initially effective, but patients will eventually relapse and become resistant to their treatment. Therefore, there is a dire need to understand more about metastatic prostate cancer to identify novel therapeutic targets towards curing this disease.
Combining forces, Dr Philip Gregory, Professor Greg Goodall and Associate Professor Simon Conn from the CCB have identified a new molecular pathway that is likely to control whether a prostate cell remains benign or becomes more aggressive and metastasizes.
We are delighted to fund their pilot project, which will examine this pathway in metastatic prostate cancer samples from patients to assess its importance for patient outcomes to develop new treatments for advanced prostate cancer.
“We are thrilled to be supported by The Hospital Research Foundation to get this project underway and contribute to a future free of prostate cancer. A pilot project is essential for us to get the initial data we need to take this research to the next phase,” said Dr Gregory.
We look forward to updating you on the outcomes of this exciting project in the near future.
would you like to support lifesaving research?